Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0001628171
$194.28
-1.15% · delayed ~15 min
Last price from Oct 21, 2026
$38.27B market value
From Revolution Medicines, Inc.'s FY2025 10-K, filed Feb 25, 2026 · read the filing
Revolution Medicines develops and makes medicines. It took in $0.00 last year, which makes it a small company.
The filing does not provide enough evidence for a clear financial conclusion.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Significant financial weakness across most measures.
From Revolution Medicines, Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
-$689.5M → -$1.18B
Profit
-$600.1M → -$1.13B
Free cash flow
-$567.7M → -$913.7M
Earnings per share
-$3.23 → -$5.74
Measured against FY2024, from the 10-K filed Feb 25, 2026
Deteriorated: $492.8M wider
-$689.5M to -$1.18BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: $531.2M wider
-$600.1M to -$1.13BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
RVMD fell 1.15% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 2.8 points below its sector and in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 29 analysts covering this company, as of . Their views, not this site's.
Of 29 analysts publishing on this company, 10 say strong buy, 17 say buy and 2 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $1.13B last year.
Not enough history has been reported to judge growth.
It does not appear so. For every $1 it owes, it owns $3.26 in assets. Its operating profit does not cover its interest bill — -48.80x against the interest it owes.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $1.13B and generated -$897.7M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 25, 2026Filing for FY2025 | FY202410-K · Feb 25, 2026Filing for FY2024 | FY202310-K · Feb 25, 2026Filing for FY2023 | FY202210-K · Feb 27, 2023Filing for FY2022 | FY202110-K · Feb 28, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M | n/m |
| Selling, general and administrative | $195.0M | $97.3M | $75.6M | $40.6M | $30.4M | +100.5% |
| Operating income | -$1.18B | -$689.5M | -$487.2M | -$258.3M | -$188.0M | −71.5% |
| Operating marginOperating income ÷ revenueWhat is this? | — | — | -4207.1% | -730.0% | -639.7% | — |
| Interest expense | $24.2M | $0.00 | $0.00 | $0.00 | $12.0K | n/m |
| Income before tax | -$1.13B | -$600.8M | -$439.9M | -$249.1M | -$187.1M | −88.3% |
| Net income | -$1.13B | -$600.1M | -$436.4M | -$248.7M | -$187.1M | −88.5% |
| Net marginNet income ÷ revenueWhat is this? | — | — | -3768.3% | -703.0% | -636.6% | — |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-5.74 | $-3.23 | $-2.65 | $-2.75 | $-2.52 | −77.9% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| RVMDRevolution Medicines, Inc. · this page | 2.0/10 | 1/7 | — | — | — | 0.44x |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 8.7/10 | 6/8 | 8.9% | 32.9% | 34.38x | 0.37x |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 6,000 shares at $58.84 ($353.0K)
Holds 58,868 shares after this filing.
Sold on the open market — 2,200 shares at $200.82 ($441.8K)
Holds 56,668 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Took on a direct financial obligation · Reported another event
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingWrite down why you are following Revolution Medicines, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 6 subsidiaries named in its 10-K, incorporated across 4 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Source: Exhibit 21 of the 10-K filed 2026-02-25. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from RVMD's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 25, 2026), reported under the US GAAP taxonomy. View the source filing.
2 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Growth and Accounting had too few reported figures and are left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 7 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 2.0 | 1/7 | 10-K, filed Feb 25, 2026 |
| FY2024 | 4.7 | 2/7 | 10-K, filed Feb 26, 2025 |
| FY2023 | 4.7 | 2/7 | 10-K, filed Feb 26, 2024 |
| FY2022 | 4.7 | 3/7 | 10-K, filed Feb 27, 2023 |
| FY2021 | 2.0 | 2/7 | 10-K, filed Feb 28, 2022 |
| FY2020 | 2.0 | 2/7 | 10-K, filed Mar 2, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
1 of 7 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. 2 could not be evaluated and are excluded from the total rather than counted as failures.
29.30
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: $346.0M wider
-$567.7M to -$913.7MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: $2.51 wider
-$3.23 to -$5.74Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Changed: +55.1%
$10.3M to $16.0MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: -29.3%
$543.1M to $383.7MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +6.0%
185.9M to 197.0MSignificant
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Deteriorated: $240.4M wider
-$264.7M to -$505.1MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: $396.6M wider
-$247.8M to -$644.4MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: $1.68 wider
-$1.33 to -$3.01Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +102.6%
$402.4M to $815.4MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +14.6%
186.9M to 214.2MCritical
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: $190.6M wider
-$453.8M to -$644.4MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +84.9%
$440.9M to $815.4MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: $0.74 wider
-$2.27 to -$3.01Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +7.0%
200.2M to 214.2MSignificant
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Deteriorated: $59.9M wider
-$445.2M to -$505.1MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 6.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
This company has not reported enough of the required figures to calculate this score.
| 6.0/10 |
| 3/9 |
| -39.9% |
| -145.2% |
| — |
| 0.43x |
| REGNREGENERON PHARMACEUTICALS, INC. | 8.7/10 | 6/8 | 1.0% | 31.4% | 19.02x | 0.30x |
|---|
| BIIBBIOGEN INC. | 9.0/10 | 6/9 | 2.2% | 13.1% | 28.82x | 0.61x |
|---|
| ALNYALNYLAM PHARMACEUTICALS, INC. | 7.3/10 | 5/8 | 65.2% | 8.4% | 95.89x | 5.29x |
|---|
| Median of peers | 8.7/10 | — | 2.2% | 13.1% | 31.60x | 0.43x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 1,609 shares at $201.72 ($324.6K)
Holds 55,059 shares after this filing.
Sold on the open market — 1,000 shares at $202.81 ($202.8K)
Holds 54,059 shares after this filing.
Sold on the open market — 1,199 shares at $203.91 ($244.5K)
Holds 52,860 shares after this filing.
Sold on the open market — 301 shares at $204.72 ($61.6K)
Holds 52,559 shares after this filing.
Sold on the open market — 765 shares at $207.32 ($158.6K)
Holds 51,776 shares after this filing.
Sold on the open market — 587 shares at $200.00 ($117.4K)
Holds 39,765 shares after this filing.
Exercised stock options — 3,121 shares at $33.62 ($104.9K)
Holds 42,886 shares after this filing.
Sold on the open market — 3,121 shares at $200.54 ($625.9K)
Holds 39,765 shares after this filing.
Exercised stock options — 5,070 shares at $1.12 ($5.7K)
Holds 14,476 shares after this filing.
Sold on the open market — 910 shares at $191.85 ($174.6K)
Holds 13,566 shares after this filing.
Sold on the open market — 4,985 shares at $192.54 ($959.8K)
Holds 8,581 shares after this filing.
Sold on the open market — 2,648 shares at $193.44 ($512.2K)
Holds 5,933 shares after this filing.
Sold on the open market — 1,500 shares at $194.59 ($291.9K)
Holds 4,433 shares after this filing.
Sold on the open market — 100 shares at $195.15 ($19.5K)
Holds 4,333 shares after this filing.
Sold on the open market — 1,764 shares at $196.94 ($347.4K)
Holds 40,352 shares after this filing.
Sold on the open market — 85 shares at $195.01 ($16.6K)
Holds 291,791 shares after this filing.
Sold on the open market — 5,484 shares at $199.30 ($1.1M)
Holds 286,307 shares after this filing.
Sold on the open market — 27 shares at $195.05 ($5.3K)
Holds 43,863 shares after this filing.
Sold on the open market — 1,747 shares at $199.30 ($348.2K)
Holds 42,116 shares after this filing.
Sold on the open market — 5 shares at $194.96 ($974.79)
Holds 53,204 shares after this filing.
Sold on the open market — 336 shares at $199.30 ($67.0K)
Holds 52,868 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 6,309 shares ($1.3M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 9,363 shares ($1.9M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 587 shares ($112.0K) on or after .
Shares originally obtained via Restricted Stock Units.
Filed notice to sell 15,080 shares ($2.9M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 1,764 shares ($347.4K) on or after .
Shares originally obtained via Restricted Stock Units.
Filed notice to sell 331 shares ($67.4K) on or after .
Shares originally obtained via RSU vesting.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Reported another event
Quarterly report for Q2 FY2026
Operating income $240.4M wider · Profit $396.6M wider · Earnings per share $1.68 wider — against Q2 FY2025
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Operating income $204.5M wider · Profit $240.4M wider · Free cash flow $158.0M wider — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingSigned a material agreement · Took on a direct financial obligation · Reported another event
Read the filingReported another event
Read the filingReported another event
Read the filingAnnual report for FY2025
Operating income $492.8M wider · Profit $531.2M wider · Free cash flow $346.0M wider — against FY2024
Read the filingPublished results
Read the filingQuarterly report for Q3 FY2025
Operating income $139.6M wider · Profit $148.9M wider · Earnings per share $0.68 wider — against Q3 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Operating income $108.1M wider · Profit $114.6M wider · Earnings per share $0.52 wider — against Q2 FY2024
Read the filingPublished results
Read the filingCoverage from the last 30 days
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Yahoo Finance ·
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance ·
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Yahoo Finance ·
Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?
Yahoo Finance ·
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Yahoo Finance ·
Revolution Medicines Stock In Focus After EU Drug Backing
Yahoo Finance ·
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
Yahoo Finance ·
IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance
Yahoo Finance ·
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Yahoo Finance ·
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Yahoo Finance ·
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
Yahoo Finance ·
First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
Yahoo Finance ·
Primary sources and further research